Caicun Zhou, M., Silvia Novello, M., Pilar Garrido, M., Christophe Dooms, M., Jorge Alatorre-Alexander, M., Niels Reinmuth, M., . . . Koichi Goto, M. (2025). Patient-Reported Outcomes From LIBRETTO-431: First-Line Selpercatinib Versus Chemotherapy With Pembrolizumab in RET Fusion-Positive NSCLC. Elsevier.
Chicago Style (17th ed.) CitationCaicun Zhou, MD, et al. Patient-Reported Outcomes From LIBRETTO-431: First-Line Selpercatinib Versus Chemotherapy With Pembrolizumab in RET Fusion-Positive NSCLC. Elsevier, 2025.
MLA (9th ed.) CitationCaicun Zhou, MD, et al. Patient-Reported Outcomes From LIBRETTO-431: First-Line Selpercatinib Versus Chemotherapy With Pembrolizumab in RET Fusion-Positive NSCLC. Elsevier, 2025.
Warning: These citations may not always be 100% accurate.